miRNA Therapeutic Composition for Solid Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies using miRNAs, such as miR-22 and miR-34, have limited therapeutic effects against various types of cancer, and there is a need for miRNAs with stronger cancer therapeutic effects.
Innovation Solution
A pharmaceutical composition comprising transcription or processing products of specific miRNAs, including miR-3140, miR-137, miR-631, and miR-657, which are chemically modified and used in combination with nucleic acid transfection agents for targeted cancer therapy, particularly for solid cancers like colon, pancreatic, and lung cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional miRNAs (miR-22, miR-34) are used for cancer therapy, then therapeutic effect is achieved, but the therapeutic effect is limited and insufficient
Solution Approach 1:
The patent identifies and utilizes specific miRNA sequences (miR-3140, miR-137, miR-631, miR-657) that have been optimized to achieve stronger cancer therapeutic effects compared to conventional miRNAs. This involves changing the parameter of miRNA sequence selection to achieve superior therapeutic efficacy while maintaining reliability.
2Reliability
If miRNA therapy is developed, then cancer treatment option is provided, but delivery efficiency and targeting accuracy are insufficient
Solution Approach 1:
The patent employs transfection agents as intermediary substances to facilitate the delivery of miRNA into cancer cells. These transfection agents act as mediators that enhance the uptake and expression of miRNA therapeutics, thereby improving delivery efficiency and targeting accuracy without compromising the therapeutic effect.
3Reliability
If miRNA sequences are modified chemically, then stability and efficacy are improved, but complexity of composition preparation increases
Solution Approach 1:
The patent applies chemical modifications to miRNA sequences (such as LNA-tion, BNA-tion, ENA-ation, 2′-OMe modification, phosphorothioation) to enhance stability and efficacy. By carefully selecting and optimizing these chemical parameters, the patent achieves improved therapeutic performance while managing the complexity of preparation through standardized modification protocols.
Data Source
AI summary
The object of the present invention is to find a pharmaceutical having strong cancer therapeutic effect. The present invention provides a pharmaceutical composition for cancer therapy comprising a transcription or processing product of a gene encoding a miRNA, wherein said miRNA is one or more miRNAs selected from the group consisting of miR-3140, miR-137, miR-631, and miR-657, pharmaceutical composition.